Invasive cutaneous malignant melanoma in Sweden, 1990-1999: A prospective, population-based study of survival and prognostic factors

Cancer

Volumn 101, Issue 9, 2004, Pages 2067-2078

  Lindholm, Christer ^a,c   Andersson, Ronny ^b   Dufmats, Monika ^c   Hansson, Johan ^d   Ingvar, Christian ^e   Möller, Torgil ^e   Sjödin, Helena ^d   Stierner, Ulrika ^f   Wagenius, Gunnar ^g  

^a RYHOV COUNTY HOSPITAL   (Sweden)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^g UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cutaneous malignant melanoma; Incidence; Population based; Prognostic factors; Prospective; Survival

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CANCER INVASION; CANCER LOCALIZATION; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CLOTHING; EARLY DIAGNOSIS; FEMALE; GENDER; HEALTH CARE ACCESS; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SWEDEN; ULCER;

EID: 7044272563     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20602     Document Type: Article

References (38)

1. Ringborg U, Andersson R, Eldh J, et al. Resection margins of 2 versus 5 cm for cutaneous malignant melanoma with a tumor thickness of 0.8 to 2.0 mm: randomized study by the Swedish Melanoma Study Group. Cancer. 1996;77:1809-1814.
2. Cohn-Cedermark G, Rutqvist L-E, Andersson R, et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer. 2000;89:1495-1501.
3. Ringborg U, Afzelius L-E, Lagerlöf B, et al. Cutaneous malignant melanoma of the head and neck. Cancer. 1993;71:751-758.
4. Hansson J, Ringborg U, Lagerlöf B, et al. Elective lymph node dissection in stage I cutaneous malignant melanoma of the head and neck. A report from the Swedish Melanoma Study Group. Melanoma Res. 1994;4:407-411.
5. Jungnelius U, Ringborg U, Aamdal S, et al. Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised Phase III trial. Eur J Cancer. 1998;9:1368-1374.
6. Hafstrom L, Rudenstam CM, Blomquist E, et al. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group. [see comments.]. J Clin Oncol. 1991;9:2091-2094.
7. Balch C, Buzaid A, Soong S-J, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-3648.
8. International Union Against Cancer (UICC). TNM classification of malignant tumors. Geneva: UICC, 1977.
9. Mattsson B, Wallgren A. Completeness of the Swedish cancer register. Acta Radiol Oncol. 1984;23:305-313.
10. Nystrom L, Larsson LG, Rutqvist LE, et al. Determination of cause of death among breast cancer cases in the Swedish randomized mammography screening trials. A comparison between official statistics and validation by an endpoint committee. Acta Oncol. 1995;34:145-152.
11. National Board of Health and Welfare. Cancer incidence in Sweden 1999. Stockholm: The National Board of Health and Welfare Center for Epidemiology, 2001.
12. Fleiss JL. The standardization of rates and statistical methods for rates and proportions, 2nd ed. New York: John Wiley & Sons, 1981.
13. Altman DG. Comparing groups. Continuous data. In: Altman DG, editor. Practical statistics for medical research, 1st ed. London: Chapman & Hall, 1997:179-223.
14. Daniel WW. Biostatistics: a foundation for analysis in the health science, 6th ed. New York: John Wiley & Sons, 1995.
15. Armitage P, Berrry G. Statistical methods in medical research, 3rd ed. Oxford: Blackwell Science Ltd., 1994.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
17. Hakulinen T. Cancer survival corrected for heterogeneity in patient withdrawal. Biometrics. 1982;38:933-942.
18. Parkin DM, Whelan SL, Ferlay J, et al., editors. Cancer incidence in five continents, vol VII. Lyon: IARC Scientific Publications, 1997.
19. Veronesi U, Cascinelli N. Narrow excision (1-cm margin): a safe procedure for thin cutaneous melanoma. Arch Surg. 1991;126:438-441.
20. Marrett L, Nguyen H, Armstrong B. Trends in the incidence of cutaneous melanoma in New South Wales, 1983-1996. Int J Cancer. 2001;92:457-462.
21. Jemal A, Devesa S, Hartge P, Tucker M. Recent trends in cutaneous melanoma incidence among whites in the United States. J Natl Cancer Inst. 2001;93:678-683.
22. Czarnecki D, Meehan CJ. Is the incidence of malignant melanoma decreasing in young Australians? J Am Acad Dermatol 2000;42:672-674.
23. Hemminki K, Li X, Czene K. Cancer risk in first-generation immigrants to Sweden. Int J Cancer. 2002;99:218-228.
24. Bray F, Sankila R, Ferlay J, Parkin DM. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer. 2002;38:99-166.
25. Masback A, Westerdahl J, Ingvar C, Olsson H, Jonsson N. Cutaneous malignant melanoma in southern Sweden 1965, 1975, and 1985. A histopathologic review. Cancer. 1994;73:1625-1630.
26. Månsson-Brahme E, Johansson H, Singnomklao T, Larsson O, Rutqvist LE, Ringborg U. Time-trends in survival in cutaneous malignant melanoma; a population-based study in Sweden. In: Cutaneous malignant melanoma. Aspects on prognostical factors and time-trends in a Swedish population [thesis]. Paper II, 1-28. Stockholm: Karolinska University Press, 2002.
27. Garbe C, Roderick C, Mc Leod C, Buettner G. Time trends of cutaneous melanoma in Queensland, Australia, and Central Europe. Cancer. 2000;89:1269-1278.
28. Parkin DM, Muir CS, Whelan SL, Gao YY, Ferlay J, Powell J, editors. Cancer incidence in five continents, vol VI. IARC Scientific Publication no. 120. Lyon: IARC, 1992:743, 835.
29. Magnus K. The Nordic profile of skin cancer incidence. A comparative epidemiological study of the three main types of skin cancer. Int J Cancer. 1991;47:12-9.
30. Thörn M, Ponten F, Bergstrom R, Sparen P, Adami HO. Trends in tumour characteristics and survival of malignant melanoma 1960-84: a population-based study in Sweden. Br J Cancer. 1994;70:743-748.
31. Masback A, Westerdahl J, Ingvar C, Olsson H, Jonsson N. Cutaneous malignant melanoma in southern Sweden 1965, 1975, and 1985. Prognostic factors and histologic correlations. Cancer. 1997;79:275-283.
32. Thörn M, Adami H-O, Bergström R, Ringborg U, Krusemo UB. Trends in survival from malignant melanoma: remarkable improvement in 23 years. J Natl Cancer Inst. 1989;81:611-617.
33. Smith JAE, Whatley PM, Redburn JC, and the EUROCARE Working Group. Improving survival of melanoma patients in Europe since 1978. Eur J Cancer. 1998;34:2197-2203.
34. Sant M, Capocaccia R, Coleman MP, et al. Cancer survival increases in Europe, but international differences remain wide. Eur J Cancer. 2001;37:1659-1667.
35. La Vechia C, Lucchini F, Negri E, Levi F. Recent declines in worldwide mortality from cutaneous melanoma in youth and middle age. Int J Cancer. 1999;81:62-66.
36. Cohn-Cedermark G, Månsson-Brahme E, Johansson H, et al. Trends in mortality from malignant melanomas in Sweden 1970-1996. Cancer. 2000;89:348-355.
37. Prade M, Sancho-Granier H, Cesarini JP, Cochran A. EORTC Melanoma Pathologist's Group. Difficulties encountered in the application of Clark classification and the Breslow thickness measurement in cutaneous melanoma. Int J Cancer. 1980;26:159-163.
38. Balch C, Soong S-J, Gershenwald, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622-3634.